

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
-----MATERIAL NAME: Levophed, Norepinephrine Bitartrate Injection, USP
List Number: 1443MANUFACTURER: Hospital Products Division
Abbott Laboratories
Abbott Park, Illinois 60064EMERGENCY TELEPHONE NUMBER: 1-847-937-7970
CHEMTREC TELEPHONE NUMBER: 1-800-424-93002. COMPOSITION/INFORMATION ON INGREDIENTS
-----INGREDIENT NAME: Norepinephrine *
CAS/RTECS NUMBERS: 51-41-2 / DN5950000
OSHA-PEL 8HR TWA: N/L
STEL: N/L
CEILING: N/L
ACGIH-TLV 8HR TWA: N/L
STEL: N/L
CEILING: N/L
OTHER 8HR TWA: 0.5 mcg/m3, skin (norepinephrine) (Abbott
Laboratories)
LIMITS STEL: 5 mcg/m3 **
CEILING: N/A

* Hazardous per OSHA criteria

** Up to four excursions allowed, no closer than 1 hour apart, so long
as the 8-hour TWA is maintained.3. HAZARDS INFORMATION
-----EMERGENCY OVERVIEW: In clinical use, this material is used to stimulate
the sympathetic nervous system and the heart. The active
ingredient, norepinephrine is highly toxic by ingestion and toxic by
skin absorption. It is a potent drug. Target organs include the
cardiovascular system, nervous system, reproductive system and
fetus.

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

3. HAZARDS INFORMATION, continued

ROUTE(S) OF ENTRY: Skin: Unlikely
 Inhalation: Unlikely
 Ingestion: Unlikely

INGESTION RATING: Possibly highly toxic.

SKIN ABSORPTION RATING: Possibly toxic

INHALATION RATING: N/D

CORROSIVENESS RATING: N/D

SKIN CONTACT RATING: N/D

SKIN SENSITIZATION RATING: N/D

EYE CONTACT RATING: Possible irritant

TARGET ORGANS: Cardiovascular system, nervous system, reproductive system, fetus.

CARCINOGENICITY RATING: NTP: N/L IARC: N/L OSHA: N/L
ACGIH: N/L
None

SIGNS AND SYMPTOMS: N/D. In clinical use, norepinephrine can produce many side effects including slowed heart rate, restlessness, palpitations, tremors, weakness, headache, elevated blood pressure, arrhythmias, and electrolyte imbalance. Chronic inhalation could result in nasal congestion.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Clinical data suggest cardiovascular disease, blood volume deficiencies, or thrombotic ailments. Concurrent use of monoamine oxidase inhibitors or use in conjunction with cyclopropane or halothane anesthesia. Hypersensitivity to sympathomimetic amine, blood volume deficiencies, or thrombotic ailments.

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

4. FIRST AID MEASURES

EYES: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

SKIN: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

INGESTION: Remove from source of exposure. Seek immediate medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

INHALATION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

5. FIRE FIGHTING PROCEDURES

FLASH POINT: Non-flammable

FLASH POINT METHOD: N/A

LOWER EXPLOSIVE LIMIT(%): N/D

UPPER EXPLOSIVE LIMIT(%): N/D

AUTOIGNITION TEMPERATURE: N/A

FIRE & EXPLOSION HAZARDS: N/D

EXTINGUISHING MEDIA: Use media appropriate for primary cause of fire.

FIRE FIGHTING INSTRUCTIONS: Fire fighters should wear self-contained breathing apparatus, fire and chemical resistant clothes, boots and gloves.

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

6. ACCIDENTAL RELEASE MEASURES

SPILL OR RELEASE PROCEDURES: Absorb with suitable material and place in appropriate container for disposal in accordance with Section 13.

7. HANDLING AND STORAGE

HANDLING: Protect from light.

STORAGE: Store at room temperature up to 30 deg. C (86 deg. F)

SPECIAL PRECAUTIONS: Protect from light.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ENGINEERING CONTROLS: No special provisions are required under normal product use conditions.

RESPIRATORY PROTECTION: Not needed during normal product use.

SKIN PROTECTION: If skin contact is likely, impervious gloves are recommended.

EYE PROTECTION: Recommended if eye contact is likely.

OTHER PROTECTION: N/D

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: Clear, colorless or practically colorless liquid.

ODOR: N/D

BOILING POINT: Water (approx.)

MELTING/FREEZING POINT: Water (approx.)

VAPOR PRESSURE (mm Hg): N/D

VAPOR DENSITY (Air=1): N/D

EVAPORATION RATE: N/D

BULK DENSITY: 1.006 - 1.008 g/mL

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

9. PHYSICAL AND CHEMICAL PROPERTIES, continued

SPECIFIC GRAVITY: N/D

SOLUBILITY: Highly soluble in water.

pH: 3.0 - 4.5

VISCOSITY: N/D

10. STABILITY AND REACTIVITY

CHEMICAL STABILITY: stable.

INCOMPATIBILITIES: N/D

HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition it emits toxic fumes of NOx.

HAZARDOUS POLYMERIZATION: N/D

11. TOXICOLOGICAL INFORMATION

ORAL TOXICITY: N/D. LD50 = 20 mg/kg in mice. (norepinephrine).

DERMAL TOXICITY: N/D. LC50(SC) = 5.0-7.6 mg/kg in mice (norepinephrine).

INHALATION TOXICITY: N/D

CORROSIVENESS: N/D

DERMAL IRRITATION: N/D

OCULAR IRRITATION: N/D. Local vasoconstriction could result in eye irritation. (Norepinephrine).

DERMAL SENSITIZATION: N/D

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

11. TOXICOLOGICAL INFORMATION, continued

SPECIAL TARGET ORGAN EFFECTS: N/D. Norepinephrine is a naturally occurring sympathomimetic amine that stimulates the sympathetic nervous system. Has been reported to produce adverse effects on fertility and on the fetus in animal studies. Use during pregnancy can cause uterine contractions that can lead to fetal anoxia. Chronic inhalation of a similar material, epinephrine, has resulted in chronic nasal congestion due to local vasoconstriction.

CARCINOGENICITY INFORMATION: N/D

12. ECOLOGICAL INFORMATION

ECOLOGICAL INFORMATION: N/D

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHODS: Dispose of in accordance with local, state and federal regulations.

14. TRANSPORTATION INFORMATION

DOT STATUS: Not Regulated
PROPER SHIPPING NAME: N/D
HAZARD CLASS: N/D
UN NUMBER: N/D
PACKING GROUP: N/D
REPORTABLE QUANTITY: N/D

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

14. TRANSPORTATION INFORMATION, continued

IATA/ICAO STATUS: Not Regulated

PROPER SHIPPING NAME: N/D

HAZARD CLASS: N/D

UN NUMBER: N/D

PACKING GROUP: N/D

REPORTABLE QUANTITY: N/D

IMO STATUS: Not Regulated

PROPER SHIPPING NAME: N/D

HAZARD CLASS: N/D

UN NUMBER: N/D

PACKING GROUP: N/D

REPORTABLE QUANTITY: N/D

FLASH POINT: Non-flammable

15. REGULATORY INFORMATION

TSCA STATUS: N/A

CERCLA STATUS: N/A

SARA STATUS: N/A

RCRA STATUS: N/A

PROP 65 (CA): N/A

Levophed, Norepinephrine Bitartrate Injection, USP

ISSUED 08/18/98

16. OTHER INFORMATION

LEGEND: N/A = Not Applicable
N/D = Not Determined
N/L = Not Listed
L = Listed
C = Ceiling
S = Short-term
(R) = Registered Trademark of Abbott Laboratories
(TM) = Registered Trademark of Abbott Laboratories

The information and recommendations contained herein are based upon tests believed to be reliable. However, Abbott Laboratories does not guarantee their accuracy or completeness nor shall any of this information constitute a warranty, whether expressed or implied, as to the safety of the goods, the merchantability of the goods, or the fitness of the goods for a particular purpose. Adjustment to conform with actual conditions of usage may be required. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages arising from the use of these data. No freedom from infringement of any patent, copyright or trademark is to be inferred.

APPROVED BY: DLF